Decreased concentration of adiponectin together with a selective reduction of its high molecular weight oligomers is involved in metabolic complications of myotonic dystrophy type 1

European Journal of Endocrinology

Volumn 165, Issue 6, 2011, Pages 969-975

  Daniele, Aurora ^a,b,c   De Rosa, Anna ^a   De Cristofaro, Mario ^b   Monaco, Maria Ludovica ^a,c   Masullo, Mariorosario ^d   Porcile, Carola ^e   Capasso, Mario ^a   Tedeschi, Gioacchino ^b   Oriani, Giovannangelo ^a,e   Di Costanzo, Alfonso ^e  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c IRCCS SDN   (Italy)

^d UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^e UNIVERSITY OF MOLISE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH MOLECULAR WEIGHT OLIGOMER; OLIGOMER; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPONECTIN GENE; ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL FILTRATION; GENE; GENETIC ANALYSIS; HOMEOSTASIS MODEL ASSESSMENT; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; MCAULEY INDEX; METABOLIC DISORDER; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RATING SCALE; WAIST CIRCUMFERENCE; WESTERN BLOTTING;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; PROTEIN MULTIMERIZATION; YOUNG ADULT;

EID: 81555222575     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0537     Document Type: Article

References (33)

1. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD & Palin MF. Adiponectin action from head to toe. Endocrine 2010 37 11-32. (doi:10.1007/s12020-009-9278-8)
2. Gable DR, Hurel SJ & Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006 188 231-244. (doi:10.1016/j. atherosclerosis.2006.02.010)
3. Lang K & Ratke J. Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Communication and Signaling 2009 7 27. (doi:10.1186/1478-811X-7-27)
4. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K & Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Investigation 2006 116 1784-1792. (doi:10.1172/JCI29126)
5. Daniele A, Cammarata R, Pasanisi F, Finelli C, Salvatori G, Calcagno G, Bracale R, Labruna G, Nardelli C, Buono P, Sacchetti L, Contaldo F &Oriani G. Molecular analysis of the adiponectin gene in severely obese patients from Southern Italy. Annals of Nutrition and Metabolism 2008 53 155-161. (doi:10.1159/000172976)
6. Wang Y, Lam KS, Yau MH & Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochemical Journal 2008 409 623-633. (doi:10.1042/BJ20071492)
7. Machuca-Tzili L, Brook D & Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle and Nerve 2005 32 1-18. (doi:10.1002/mus.20301)
8. Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, Kondo R, Reddy S, Dillmann WH, Palacin M, Zorzano A, Ruiz-Lozano P, Gomis R & Kaliman P. Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS ONE 2007 2 e1134. (doi:10.1371/journal.pone.0001134)
9. Savkur RS, Philips AV & Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nature Genetics 2001 29 40-47. (doi:10.1038/ng704)
10. Johansson A, Carlström K, Ahrén B, Cederquist K, Krylborg E, Forsberg H & Olsson T. Abnormal cytokine and adrenocortical hormone regulation in myotonic dystrophy. Journal of Clinical Endocrinology and Metabolism 2000 85 3169-3176. (doi:10.1210/jc.85.9.3169)
11. Day JW & Ranum LPW. RNA pathogenesis of the myotonic dystrophies. Neuromuscular Disorders 2005 15 5-16. (doi:10.1016/j.nmd.2004.09.012)
12. Fernández-Real JM, Molina A, Broch M, Ricart W, Gutiérrez C, Casamitjana R, Vendrell J, Soler J & Gómez-Sáez JM. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes 1999 48 1108-1112. (doi:10.2337/diabetes.48.5.1108)
13. Zhang L, Lee JE, Wilusz J & Wilusz CJ. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. Journal of Biological Chemistry 2008 283 22457-22463. (doi:10.1074/jbc.M802803200)
14. Matsumura T, Iwahashi H, Funahashi T, Takahashi MP, Saito T, Yasui K, Saito T, Iyama A, Toyooka K, Fujimura H & Shinno S. A cross-sectional study for glucose intolerance of myotonic dystrophy. Journal of the Neurological Sciences 2009 276 60-65. (doi:10.1016/j.jns.2008.08.037)
15. Abe H, Mita T, Kudo K, Funayama T, Tokoro M, Kaga H, Ikeda F, Kanazawa A, Hirose T, Kawamori R & Wada H. Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy. Endocrine Journal 2009 56 911-913. (doi:10.1507/endocrj.K09E-122)
16. Di Costanzo A, Santoro L, de Cristofaro M, Manganelli F, Di Salle F & Tedeschi G. Familial aggregation of white matter lesions in myotonic dystrophy type 1. Neuromuscular Disorders 2008 18 299-305. (doi:10.1016/j.nmd.2008.01.008)
17. Shaw LJ, Peterson ED, Kesler K, Hasselblad V & Califf RM. A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. American Journal of Cardiology 1996 78 1327-1337. (doi:10.1016/S0002-9149(96)00653-4)
18. Wijeysundera DN, Rao V, Beattie WS, Ivanov J & Karkouti K. Evaluating surrogate measures of renal dysfunction after cardiac surgery. Anesthesia and Analgesia 2003 96 1265-1273. (doi:10.1213/01.ANE.0000056824.69668.33)
19. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A & Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003 26 3320-3325. (doi:10.2337/ diacare.26.12.3320)
20. Daniele A, Cammarata R, Masullo M, Nerone G, Finamore F, D'Andrea M, Pilla F & Oriani G. Analysis of adiponectin gene and comparison of its expression in two different pig breeds. Obesity 2008 16 1869-1874. (doi:10.1038/oby.2008.275)
21. Rakocevic Stojanovic V, Peric S, Lavrnic D, Popovic S, Ille T, Stevic Z, Basta I & Apostolski S. Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. Acta Neurologica Scandinavica 2010 121 94-98. (doi:10.1111/j.1600-0404.2009.01237.x)
22. Sulpice T, Prunet-Marcassus B, Molveaux C, Cani PD, Vitte PA, Graber P, Dreano M & Burcelin R. An adiponectin-like molecule with antidiabetic properties. Endocrinology 2009 150 4493-4501. (doi:10.1210/en.2008-1768)
23. Hirose H, Yamamoto Y, Seino-Yoshihara Y, Kawabe H & Saito I. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. Journal of Atherosclerosis and Thrombosis 2010 17 1201-1211. (doi:10.5551/jat.6106)
24. Nishida M, Funahashi T & Shimomura I. Pathophysiological significance of adiponectin. Medical Molecular Morphology 2007 40 55-67. (doi:10.1007/s00795-007-0366-7)
25. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A &Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. Journal of Clinical Endocrinology and Metabolism 2006 91 3873-3877. (doi:10.1210/jc.2006- 1158)
26. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, Inukai T, Okuno T & Node K. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. American Journal of Cardiology 2007 100 569-574. (doi:10.1016/j.amjcard.2007.03.062)
27. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T &Nakano Y. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006 55 1954-1960. (doi:10.2337/db05-1525)
28. Matsubara M, Maruoka S & Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. Journal of Clinical Endocrinology and Metabolism 2002 87 2764-2769. (doi:10.1210/jc.87.6.2764)
29. Koh KK, Quon MJ, Lim S, Lee Y, Sakuma I, Lee YH, Han SH &Shin EK. Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis 2011 214 144-147. (doi:10.1016/j.atherosclerosis.2010.10.023)
30. Gómez Rosso L, Meroño T, Benítez MB, Lee Y, Sakuma I, Lee YH, Han SH & Shin EK. Low adiponectin levels in primary hypertriglyceridemic male patients. Nutrition, Metabolism, and Cardiovascular Diseases 2009 19 135-139. (doi:10.1016/j.numecd.2008.02.008)
31. Cawthorn WP & Sethi JK. TNF-alpha and adipocyte biology. FEBS Letters 2008 582 117-131. (doi:10.1016/j.febslet.2007.11.051)
32. Hajri T, Tao H, Wattacheril J, Marks-Shulman P & Abumrad NN. Regulation of adiponectin production by insulin: interactions with tumor necrosis factor-a and interleukin-6. American Journal of Physiology. Endocrinology and Metabolism 2011 300 350-360. (doi:10.1152/ajpendo.00307.2010)
33. Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ, Vidal-Puig A, Jones R & Considine RV. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obesity Research 2005 13 662-669. (doi:10.1038/oby.2005.74)